TESARO, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-03-01
- Employees
- 715
- Market Cap
- -
- Website
- http://tesarobio.com
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 463
- Registration Number
- NCT02354586
- Locations
- 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT02285647
- Locations
- 🇺🇸
Parexel, Baltimore, Maryland, United States
A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT02048488
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 216
- Registration Number
- NCT01905592
- Locations
- 🇬🇧
GSK Investigational Site, Whitchurch, Cardiff, United Kingdom
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 596
- Registration Number
- NCT01847274
- Locations
- 🇬🇧
GSK Investigational Site, Taunton, United Kingdom
Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 1369
- Registration Number
- NCT01500226
- Locations
- 🇺🇸
TESARO Inc, Waltham, Massachusetts, United States
Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 555
- Registration Number
- NCT01500213
- Locations
- 🇺🇸
TESARO Inc, Waltham, Massachusetts, United States
Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 532
- Registration Number
- NCT01499849
- Locations
- 🇺🇸
TESARO Inc, Waltham, Massachusetts, United States
A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Tesaro, Inc.
- Registration Number
- NCT01244009
MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01227941
© Copyright 2024. All Rights Reserved by MedPath